morf-057
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 23, 2020 (NCT04580745)
Timeline
Indications
Mechanism of action
- Unspecified targetANTAGONIST
antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07186101 | Phase 2 | Nov 11, 2025 | Eli Lilly |
| NCT06964776 | Phase 1 | May 1, 2025 | Eli Lilly |
| NCT06226883 | Phase 2 | Apr 4, 2024 | Morphic Therapeutic, Inc |
| NCT05611671 | Phase 2 | Oct 31, 2022 | Morphic Therapeutic, Inc |
| NCT05291689 | Phase 2 | May 24, 2022 | Morphic Therapeutic, Inc |
| NCT04580745 | Phase 1 | Sep 23, 2020 | Morphic Therapeutic, Inc |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Morphic Therapeutic, Inc | For profit | 4 | 4 | 2 | 2020 |
| Eli Lilly | For profit | 2 | 2 | 2 | 2025 |
2 organizations
Page 1 / 1